Clinical Trial Update: Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating LDE225 (sonidegib) in combination with docetaxel in advanced triple-negative breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• LDE225 (sonidegib) (sonidegib)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Advanced Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2018-12-04